|
Acamprosate Treatment: Mechanisms of Action Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Acamprosate Treatment: Mechanisms of Action conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Acamprosate Treatment: Mechanisms of Action Clinical research trials and Acamprosate Treatment: Mechanisms of Action medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Acamprosate Treatment: Mechanisms of Action. Acamprosate Treatment: Mechanisms of Action Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Acamprosate Treatment: Mechanisms of Action clinical trial. Test subjects typically obtain the finest healthcare available for their Acamprosate Treatment: Mechanisms of Action condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Acamprosate Treatment: Mechanisms of Action  Acamprosate Treatment: Mechanisms of Action
Acamprosate Treatment: Mechanisms of Action
For Condition: Alcoholism
Status: Completed
Sponsor(s): National Institute on Alcohol Abuse and Alcoholism (NIAAA) ,
Synopsis: This study will examine whether pretreatment with two doses of acamprosate for seven days prior to abstinence lessens the intensity of acute withdrawal from alcohol compared with a placebo. Subjects will be randomly assigned to receive either one of two doses of acramprosate or placebo for seven days. This will be followed by a four- day inpatient period when withdrawal will be monitored. Additional drinking information will be obtained at a three month followup interview.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 21 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meets criteria for alcohol abuse or dependence. - Able to read English at 6th grade level or higher and to complete study evaluations. - Average weekly alcohol consumption of standard drinks of at least 25 drinks for men and 20 drinks for women. - No more than 3 days abstinence/week. Exclusion Criteria: - Current abuse or dependence on other substances, other than nicotine and marijuana. - Positive test results for opiates, cocaine, benzodiazepines and barbiturates. - Regular use of psychoactive drugs including anxiolytics and antidepressants. - Psychiatrically disabled. - Hepatocellular disease or a history of cirrhosis. - Medical conditions that would prevent the consumption of alcohol, increase the risk of complicated alcohol withdrawal, or prevent the use of acamprosate such as a history of neurological trauma or disease, seizures, delirium, or hallucinations, hepatic, cardiovascular, metabolic, endocrine, gastrointestinal, or kidney disease. - Individuals who have had any significant physical illnesses during the two weeks prior to receiving study medication or during the medication treatment period prior to the withdrawal study. - Medically detoxified from alcohol more than once within the past five years. - Alcohol withdrawal symptoms requiring management with benzodiazepines. - Females who are pregnant, nursing or not using a reliable method of birth control. - Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past six months. - Individuals who report disliking spirits and have taken investigational drug or naltrexone within 4 weeks immediately preceding admission to study. - Individuals who report any daily drug use during the thirty days prior to randomization for the following: anxiolytics, beta blockers, central nervous system stimulants, hypnotics, non-therapeutic doses of neuroleptics and antidepressants, drugs with psychotropic activity or drugs which cause excessive sedation. - Subjects who have donated blood within the past six weeks.
Total Enrollment: 120
Location and Contact Information:
Substance Abuse Treatment Unit, University of Connecticut
New Haven, Connecticut, 06511
United States
Additional Information:
Study ID Numbers: NIAAAOMA03510;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004552
Other Alcoholism Studies:
1. Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits
2. Drug Therapy for Alcohol Detoxification
3. Behavior and Naltrexone Treatment for Alcoholics
4. Naltrexone Treatment for Alcoholism
5. Improving Substance Abuse Treatment Aftercare Adherence and Outcome
Related Studies:
Other Alcoholism Clinical Trials
Other Connecticut Clinical Trials
Other New Haven Clinical Trials
Acamprosate Treatment: Mechanisms of Action
|
|
|
|
|
|
|
|
